Synthetic Biologics is a clinical-stage company developing therapeutics to address high unmet needs to treat diseases. Its lead product candidates include SYN-004 and SYN-020 designed to prevent microbiome damage, avoid infectious diseases, and treat gastrointestinal and systemic diseases. It also develops clinical stage products focusing on preventing antibiotic-associated diarrhea, treating cancer, and preventing and treating pertussis.